by 
The Asia Pacific HIV diagnostics market offers a wide range of screening assays and confirmatory assays to detect the presence of HIV antibodies or antigens in a person’s blood. HIV diagnostics products include reagents, kits, and instruments used for detection of antibodies and antigens as well as viral load and early infant diagnosis. Screening assays, confirmatory assays, viral load assays, and early infant diagnosis assays are the different types of assays used in the diagnostics process depending on the stage of infection. The increasing prevalence of HIV/AIDS in the region along with various government initiatives to spread awareness through campaigns are acting as growth drivers. The global Asia Pacific HIV Diagnostics Market is estimated to be valued at US$ 522.5 Mn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the Asia Pacific HIV diagnostics market is the rise in adoption of rapid testing. Rapid HIV tests allow for prompt detection of antibodies to HIV from oral fluid or fingerstick whole blood samples in as little as 20 minutes. They are an attractive option as they do not require venipuncture or sophisticated laboratory equipment or highly trained personnel. Various new rapid tests have entered the market in recent years offering better accuracy comparable to standard lab-based tests. Their increasing adoption especially in developing regions is expected to support market growth over the forecast period. Self-testing is another trend gaining ground where individuals can conduct HIV screening in the privacy of their homes. This helps in identifying undiagnosed infections and curbing further spread.
Porter’s Analysis
Threat of new entrants: The threat of new entrants into the Asia Pacific HIV Diagnostics market is low to moderate as it requires large capital investments and established distribution networks. New companies also need to deal with stringent regulations, certifications and long product approval times.
Bargaining power of buyers: The bargaining power of buyers in this market is high due to the presence of a large number of established players providing diagnostic tests and services. Buyers can negotiate on price and switch between different suppliers easily.
Bargaining power of suppliers: The bargaining power of suppliers in the HIV diagnostics market is moderate as the industry requires specialized equipment, reagents and components that have few substitute options. However, the dominance of few manufacturers for these inputs mitigates suppliers’ bargaining power.
Threat of new substitutes: The threat from substitutes is low as there are limited substitutes available for HIV diagnostic tests. Alternative detection methods are very niche.
Competitive rivalry: The competitive rivalry in the Asia Pacific HIV Diagnostics market is high owing to the large presence of global and regional market players offering similar testing services and price-based competition.
Key Takeaways
The Asia Pacific HIV Diagnostics market is expected to witness high growth over the forecast period 2023 to 2030 driven by growing prevalence of HIV, rising government focus, and increasing access to testing and treatment programs. The fastest growing regional markets include India, China and Southeast Asia nations supported by large population base, increasing awareness, funding initiatives and private sector participation.
Regional analysis: Within Asia Pacific, India is expected to continue dominating the market through 2030 supported by large infected population, expansion of national AIDS control programs and public-private collaborations. Low treatment coverage, high undiagnosed population and favorable government initiatives are fueling the demand. China is anticipated to emerge as the second largest and fastest growing market in Asia Pacific backed by improving healthcare infrastructure, universal healthcare reforms and economic development.
Key players operating in the Asia Pacific HIV Diagnostics market are Abbott Laboratories, Merck KGaA, F. Hoffmann-La Roche AG, Atomo Diagnostics, Siemens Healthineers, Inc., bioLytical Laboratories Inc., MedMira Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., and Danaher Corporation. Major players are focusing on new product launches, partnerships, and expanding service offerings through collaborations with communities in developing strong market presence across the region.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
